Spots Global Cancer Trial Database for Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Official Title: A Phase II Study of Oral Once Daily GW572016 (Lapatinib) In Patients With Hormone Refractory Prostate Cancer

Study ID: NCT00246753

Conditions

Prostate Cancer

Interventions

lapatinib ditosylate

Study Description

Brief Summary: RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did not respond to hormone therapy.

Detailed Description: OBJECTIVES: Primary * Determine the proportion of patients with hormone-refractory prostate cancer who experience \> 50% decline in prostate-specific antigen (PSA) after treatment with lapatinib ditosylate. Secondary * Determine the safety of this drug in these patients. * Determine the time to PSA progression in patients treated with this drug. * Determine the molecular correlates and predictive biomarkers of response in patients treated with this drug. OUTLINE: This is a multicenter, open-label study. Patients receive oral lapatinib ditosylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Serum samples are collected for biomarker analysis at baseline and every 4 weeks. After completion of study treatment, patients are followed at 4 weeks.